These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 33629745

  • 1. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M, Weng L, Xu G, Wu S, Liu B, Yin X, Mao A, Zou X, Wang Z.
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [Abstract] [Full Text] [Related]

  • 2. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 3. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.
    Oncotarget; 2015 Sep 22; 6(28):26230-41. PubMed ID: 26213847
    [Abstract] [Full Text] [Related]

  • 4. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 22; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 22; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 6. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C, Shi J, Li Q, Li Z, Lou C, Zhao Q, Zhu Y, Zhan F, Lian J, Wang B, Guan X, Fang L, Li Z, Wang Y, Zhou B, Yao Y, Zhang Y.
    Clin Sci (Lond); 2019 Mar 15; 133(5):645-663. PubMed ID: 30782607
    [Abstract] [Full Text] [Related]

  • 7. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B.
    Cancer Lett; 2017 Jul 28; 399():1-9. PubMed ID: 28428074
    [Abstract] [Full Text] [Related]

  • 8. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Duan W, Chen K, Jiang Z, Chen X, Sun L, Li J, Lei J, Xu Q, Ma J, Li X, Han L, Wang Z, Wu Z, Wang F, Wu E, Ma Q, Ma Z.
    Cancer Lett; 2017 Jan 28; 385():225-233. PubMed ID: 27773749
    [Abstract] [Full Text] [Related]

  • 9. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
    Huang W, Hu X, He X, Pan D, Huang Z, Gu Z, Huang G, Wang P, Cui C, Fan Y.
    Drug Resist Updat; 2024 May 28; 74():101079. PubMed ID: 38518727
    [Abstract] [Full Text] [Related]

  • 10. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L.
    Tumour Biol; 2016 Nov 28; 37(11):15283-15291. PubMed ID: 27696296
    [Abstract] [Full Text] [Related]

  • 11. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X, Zhao P, Wang C, Xin B.
    Biochem Biophys Res Commun; 2019 Mar 19; 510(4):508-514. PubMed ID: 30737032
    [Abstract] [Full Text] [Related]

  • 12. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, Zhuo Q, Ji S, Yu X, Xu X, Qin Y, Li Z.
    Cancer Lett; 2024 Oct 10; 602():217197. PubMed ID: 39216548
    [Abstract] [Full Text] [Related]

  • 13. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.
    Cancer Lett; 2016 Aug 28; 379(1):1-11. PubMed ID: 27233476
    [Abstract] [Full Text] [Related]

  • 14. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K.
    Cancer Lett; 2017 Sep 10; 403():296-304. PubMed ID: 28687352
    [Abstract] [Full Text] [Related]

  • 15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.
    Gastroenterology; 2015 Dec 10; 149(7):1932-1943.e9. PubMed ID: 26255562
    [Abstract] [Full Text] [Related]

  • 16. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G, Ghosh A, Gupta V, Haque I, Sarkar S, Das A, Dhar K, Bhavanasi S, Gunewardena SS, Von Hoff DD, Mallik S, Kambhampati S, Banerjee SK, Banerjee S.
    Mol Cancer Ther; 2019 Apr 10; 18(4):788-800. PubMed ID: 30787177
    [Abstract] [Full Text] [Related]

  • 17. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, Munshi HG.
    Cancer Res; 2011 Feb 01; 71(3):1019-28. PubMed ID: 21148071
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW.
    Mol Cancer; 2013 Sep 11; 12(1):104. PubMed ID: 24025152
    [Abstract] [Full Text] [Related]

  • 19. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.
    Shah A, Jahan R, Kisling SG, Atri P, Natarajan G, Nallasamy P, Cox JL, Macha MA, Sheikh IA, Ponnusamy MP, Kumar S, Batra SK.
    Cancer Lett; 2024 Aug 28; 598():217097. PubMed ID: 38964729
    [Abstract] [Full Text] [Related]

  • 20. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
    Kutschat AP, Hamdan FH, Wang X, Wixom AQ, Najafova Z, Gibhardt CS, Kopp W, Gaedcke J, Ströbel P, Ellenrieder V, Bogeski I, Hessmann E, Johnsen SA.
    Cancer Res; 2021 Jun 01; 81(11):2943-2955. PubMed ID: 33436389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.